AVertto
Agent40Agent Readiness: 40/100. Below median. Measured by StartupHub.ai. Median 41.Trust86Data Trust: 86/100. Top 25%. Measured by StartupHub.ai. Median 61.Developing a non-invasive device to detect silent strokes in high-risk populations.
About
AVertto develops medical technology that monitors, detects, and alerts to critical neurovascular events, such as stroke, by continuously analyzing carotid blood pressure waveforms. Their first commercial device, AMIT301, uses carotid biological mimicry to detect hemodynamic changes in real-time, providing clinical decision support for sedated ICU patients. This technology aims to give clinicians more time for intervention before irreversible neurological damage occurs.
Key facts
At-a-glance profile data
- Website
- avertto.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 12
- Total funding
- -
- Business model
- B2B
Tech stack
Detected on avertto.com, last scanned 20 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Cookie consent
- iubenda
Frequently asked
Is AVertto trustworthy and reputable?
StartupHub's Data Trust & Reputation score for AVertto is 86 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How many employees does AVertto have?
AVertto has approximately 12 people on record.
